Partner Hospitals

Founded in 1907, the hospital has an annual total of over 6 million outpatient and emergency visits, nearly 200,000 inpatient admissions and more than 100,000 surgeries. As Shanghai’s first medical institution offering foreign-related medical services, it is a designated medical facility for consulates of 10 countries. It has served more than 600,000 foreign patients from over 100 countries and regions worldwide.

Founded in 1997, it is one of China’s leading private hospital groups. It has established 11 hospitals and 14 clinics in Hong Kong, Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Qingdao and other cities. The annual number of patients served exceeds one million, including nearly 100,000 foreign patients. It has built a sizable international medical service network and formed a tiered medical service system of “general hospitals + specialized medical centers + clinics”. It covers a complete medical service chain including family medicine, emergency medicine, women’s health, pediatrics, cardiovascular and cerebrovascular diseases, oncology, urology, gastroenterology, orthopedics, critical care medicine and neuroscience center.

It has 7 national key experimental platforms represented by the State Key Laboratory of Kidney Diseases. The hospital is equipped with nearly 60,000 sets of sophisticated medical equipment worth nearly 7 billion RMB, including the world-leading 5th-generation CyberKnife, Da Vinci surgical robot, digital angiography machine, cyclotron, the world’s second ZAP accelerator, computed tomography therapy system, hyperbaric oxygen chamber, magnetic navigation interventional system, intraoperative radiotherapy system and cobalt-60 therapy unit.

Founded in 1869, the hospital has set national benchmarks including the “Hangzhou Protocol” for transcatheter heart valve replacement, minimally invasive complex cataract surgery, standardized diagnosis and treatment of colorectal tumors, and mass severe trauma rescue. The perioperative survival rate of pediatric liver transplantation is at the internationally leading level.

Founded in 1892, it has reached leading domestic and international standards in many fields, such as adult living donor liver transplantation, early diagnosis and treatment of lung cancer, cardiac interventional therapy, neurosurgery and functional neurosurgery, integrated traditional Chinese and Western medicine for severe pancreatitis, and allogeneic combined larynx-trachea-thyroid transplantation.

Founded in 1957, it is China’s first Grade A tertiary specialized hospital focusing on the diagnosis and treatment of cardiothoracic diseases after the founding of the People’s Republic of China. Centered on two major discipline clusters: thoracic tumors and cardiovascular diseases, it masters the most extensive spectrum and full range of diagnostic and therapeutic technologies for cardiothoracic diseases in China. Annual outpatient and emergency visits exceed 860,000, with more than 28,000 surgeries performed each year. The proportion of Grade-III and Grade-IV surgeries is over 90%. Its surgical volume for tracheal and mediastinal tumors ranks No.1 nationwide, lung tumor surgery volume ranks No.2 nationwide, and esophageal surgery volume is among the top in China and ranks No.1 in the city.

Founded in 1937. Its clinical capabilities in the fields of heart, liver, kidney, lung, digestive tract and panvascular diseases are at the top domestic and world-advanced level. The hospital is fully equipped with world-class diagnostic and therapeutic equipment including Da Vinci surgical robots, 3.0T high-field MRI, PET-CT, high-end DSA interventional systems and precision radiotherapy devices. More than 90 MDT teams have been established. Annual outpatient and emergency visits exceed 6.1 million, inpatient admissions over 280,000, and inpatient surgeries more than 210,000.